BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025 
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
NEW YORK, April 12, 2016 -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of Horizon Pharma plc securities (NASDAQ:HZNP) from March 13, 2014 through February 26, 2016, all dates inclusive (the “Class Period”). The lawsuit seeks to recover damages for Horizon Pharma investors under the federal securities laws.
To join the Horizon Pharma class action, go to the firm’s website at http://rosenlegal.com/cases-782.html or call Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected] or [email protected].
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, defendants throughout the Class Period issued materially false and misleading statements to investors and/or failed to disclose that: (1) Horizon Pharma’s Prescriptions Made Easy (“PME”) program was designed to artificially inflate the prices of minor differentiation standard retail drugs; (2) sales revenues from drugs sold through Horizon Pharma’s PME program were unsustainable at these inflated price levels; (3) Horizon Pharma’s use of its PME program left Horizon Pharma subject to increased regulatory risks, and (4) as a result, Horizon Pharma’s financial statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 9, 2016. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to the firm’s website at http://rosenlegal.com/cases-782.html for more information. You may also contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected] or [email protected].
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. Kevin Chan, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 34th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] [email protected] [email protected] www.rosenlegal.com
